Antibody Drug Conjugates Therapeutics Market - Pipeline Analysis, Size, Share and Growth, 2023

The global antibody drug conjugates therapeutics market is expected to witness significant growth due to current unmet medical need of some chronic diseases such as cancer and immunological diseases, increasing prevalence of such diseases, advancement in technologies and high demand for safe and effective medication. The regulatory bodies are supporting the ADCs market by providing designations and funding for speeding up the drug development process. In April 2015, ImmunoGen, Inc. drug candidate Mirvetuximab soravtansine got orphan drug designation by European Medicine Agency for the treatment of ovarian cancer.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market/report-sample

The pipeline of ADCs is rich with more than 200 drugs. The pharmaceutical companies are actively involved in the research and development of drug for ADCs. Trastuzumab emtansineis, a Phase III clinical trial drug candidate of Genentech, Inc., utilizes Tumor-Activated Prodrug technology for the treatment of HER2-positive primary breast cancer. The drug is already marketed under trade name Kadcyla for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer and early HER2-positive breast cancer.

ADCs are prepared by linking biologically active cytotoxic drugs to monoclonal antibodies. An ADC comprises of a monoclonal antibody, cytotoxic drug and a linker. ADCs have specific targeting ability of monoclonal antibody, and hence these are capable of distinguishing healthy and diseased cells. Moreover, the cancer-killing ability of cytotoxic drugs makes ADCs more effective against the tumor cells. These characteristics increase the specificity and maximize the efficacy of ADCs. The antibody component of ADCs recognizes the target antigen and binds with it. After binding with the antigen, the cytotoxic component is released inside the tumor cell, causing its death or degeneration. The significant potential of ADCs in cancer treatment has attracted many researchers and healthcare providers to develop new antibody therapeutics using ADC technology.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=adcs-therapeutics-market

Some of the key players operating in the global market are ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., F. Hoffmann-La Roche AG, BioAtla LLC, Philogen S.p.A., Viventia Biotechnologies, Inc., Sutro Biopharma, Inc., Sorrento Therapeutics, Inc., and Immunobiochem Corporation.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Natural Killer (NK) Cell Therapeutics Market - Pipeline Analysis, Market Size, Growth, 2023

The global natural killer cell therapeutics market is expected to witness considerable growth due to increasing awareness regarding immunotherapy, advancement in technologies, high demand for safe and effective medication, reduction of side effects, high prevalence of chronic diseases such as cancer and cardiovascular diseases, and increasing incidences of infectious diseases. The regulatory bodies are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process. Some drug candidates, such as Mogamulizumab, Lorvotuzumab Mertansine, AFM 13, FPA144, and NKTT-120, got orphan drug designation and fast track designation for NK cell therapeutics.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/nk-cell-therapeutics-market/report-sample

The pipeline of NK cell therapeutics market is rich with more than 30 drugs. The pharmaceutical companies are actively involved in the research and development of drug for NK cells. Kyowa Hakko Kirin Co., Ltd. has Mogamulizumab drug in its Phase III clinical trial for NK cells therapeutics. Increasing use of combination therapy of NK cells is also a potential growth driver for the growth of the global market. Use of NK cells with Chimeric Antigen Receptor (CAR) T-Cell therapy helps to enhance the efficacy of the medication.

The pharmaceutical companies are collaborating with each other for research and development of NK cell therapeutics. For instance, in January 2016, Sanofi and Innate Pharma entered into research collaboration and licensing agreement to apply Innate Pharma’s new proprietary technology for the development of bispecific antibody formats engaging NK cells to kill tumor cells. The drug candidate has utilized the NK cells engagers bispecific antibodies technology to create novel molecular formats for engaging NK cells for tumor cells lysis. The bispecific antibodies specifically trigger NK cells instead of T cells, which may reduce the risk of the side-effects associated with T cell engagers.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=nk-cell-therapeutics-market

However, certain factors such as side effects of NK cell medication, complex pathophysiology, and high treatment cost of NK cells are expected to hamper the growth of the global market during the forecast period.

Some of the key players operating in the global NK cells market are Chipscreen Biosciences, Ltd. Affimed N.V., Altor BioScience Corporation, Innate Pharma S.A., Takeda Pharmaceutical Company Limited, Sorrento Therapeutics Inc., NantKwest Inc., Bristol-Myers Squibb, and NKT Therapeutics, Inc.

Mammalian Target of Rapamycin Inhibitors Market - Pipeline Analysis, Market Size and Growth, 2023

The global mammalian target of rapamycin inhibitors market is witnessing considerable growth due to their application in several therapeutic areas such as cancer, renal dysfunction and eye disorders. The regulatory bodies are providing funding and designation to the drug candidates for advancement of their products. Moreover, the increasing awareness related to the effective use of mTOR inhibitors, in combination with chemotherapy and its implications in cancer therapy is also supporting the growth of global market. Different classification of mTOR inhibitors and their unique features is leading to their increased demand. Among the different generations of mTOR inhibitors, third generation mTOR inhibitors exploit the unique juxtaposition of two drug-binding pockets to create a bivalent interaction that allows inhibition of resistant mutants.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-market/report-sample

The involvement of antibiotics and proteins for drug development and technological advancements for mTOR inhibitors are expected to create ample growth opportunities for the global market. However, high cost of the marketed drugs and complexity in understanding the mechanism of action are the limitations associated with mTOR inhibitors, which are hampering the growth of the global market.

Geographically, North America was the largest market for mTOR inhibitors in 2015, owing to the large number of research and development activities, high healthcare expenditure, and high prevalence of chronic diseases such as cancer and cardiovascular diseases. The U.S. contributed largest revenue to the North American mTOR inhibitors market and it is expected to remain the largest market globally, during the forecast period. The supporting government regulations taken by the federal government is the key driving factor of the U.S. mTOR inhibitors market.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=mtor-inhibitors-market

Europe is the second largest market for mTOR inhibitors. During the forecast period, the mTOR inhibitors market would witness highest growth in Asia-Pacific, attributed to increasing number of new entrants, improving healthcare infrastructure, increasing prevalence of chroic diseases and increasing healthcare expenditure.

The key players operating in the global market are Pfizer Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Ability Pharma, GlaxoSmithKline, MEI Pharma, Verastem, Inc., Phusis Therapeutics, Inc., and Co-D Therapeutics, Inc.

Radiation Dose Management Market - Industry Research Report Analysis, Size and Growth, 2023

According to the study, the global radiation dose management market is likely to develop at a CAGR of 46.0% during 2017-2023. RDM solutions and services are offered for various imaging modalities such as computed tomography (CT), nuclear medicine, fluoroscopy and interventional imaging, radiography and mammography, and others. RDM solutions and services are mostly utilized for monitoring radiation dose in CT. Globally, certain standards have been set up by the government to avoid high dose of radiation and have linked these doses to reimbursements, so that the radiologists give priority to the new guidelines. For instance, in 2014, National Equipment Manufacturers Association (NEMA) established certain guidelines under XR-29, for promoting low radiation dose standards. According to these guidelines, if the dose standards for CT are not followed it can bring down the reimbursement, as much as 15% for CT scanners that don’t meet the standards set forward by XR-29. Therefore, stringent regulatory requirements for diagnostic techniques supports the demand for RDM solutions and services.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/radiation-dose-management-market/report-sample

As per the findings of the research, RDM solutions occupied the larger share of the global market in 2016, since these solutions enable the healthcare providers to track and evaluate the radiations emitting from different diagnostic procedures. The players in the industry provide services such as implementation and integration, support and maintenance, consulting and training and education. Among all the services, implementation and integration held the largest share of the market in 2016, since these services are associated with installation of solutions and integration with other systems in the healthcare settings.

Hospitals and super speciality clinics are the key end user of the RDM solutions and services and held largest share in 2016, mainly due to increasing number of installation of RDM solutions and growing number of diagnostic procedures in the treatment and management of diseases in the hospitals.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=radiation-dose-management-market

Globally, the key players in the market are introducing new solutions with advanced features in the market. For instance, in November 2016, Koninklijke Philips N.V. introduced DoseWise Portal 2.2, a next-generation radiation dose management software platform for healthcare providers to record, track and analyse radiation exposure to patients and clinicians.

GLOBAL RDM MARKET SEGMENTATION

By Product and Services

• ·         Solutions

o    Integrated solutions

o    Standalone solutions

• ·         Services

o    Implementation & integration services

o    Support & maintenance services

o    Consulting services

o    Training & education services

By Modality

•         Computed tomography (CT)
• ·         Nuclear medicine
• ·         Fluoroscopy & interventional imaging
• ·         Radiography & mammography
• ·         Others

By End User

·         Hospitals

·         Super specialty clinics

·         Others

By Region

• ·North America
• U.S.
• Canada
• ·Europe
• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe
•  Asia-Pacific
• Japan
• China
• India
• Rest of Asia-Pacific
• Rest of World (RoW)

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Hypertrophic Scars Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents and Developments

Body cells known as myofibroblasts produce excessive collagen during healing process which can be deposited as a bump and later changes to a hypertrophic scar. The study analyzed that the hypertrophic scars therapeutics pipeline comprises approximately nine drug candidates in different stages of development.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/hypertrophic-scars-therapeutics-pipeline-analysis/report-sample

Majority of the pipeline drug candidates are being developed to be administered by the topical route. SCX-001 cream has demonstrated anti-scarring effects in two in-vivo Pre-clinical dermal models. SCX-001 cream’s safety as a topical agent has also been confirmed in non-clinical Investigational New Drug (IND) in-vitro and in-vivo studies.

Technological advancements have been strengthening the development of pipeline drugs for the treatment of hypertrophic scars. For instance, The RNA interference (RNAi) technology, was used in the development of OLX101 by OliX Pharmaceuticals, Inc.

Pre-purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hypertrophic-scars-therapeutics-pipeline-analysis

Some of the players developing drugs for the treatment of hypertrophic scars include RXi Pharmaceuticals Corporation, Sirnaomics, Inc., ScarX Therapeutics, Inc., and Scarless Laboratories, Inc.

IL-6 Inhibitors Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents and Collaborations

The study analyzed that the IL-6 inhibitorstherapeutics pipeline comprises approximately 18 active drug candidates in different stages of development. Interleukin-6 inhibitors acts on the IL-6 receptor. IL-6 receptors belong to a group of cytokine receptors that are expressed by leukocytes and plays an important role in the functioning of the immune system. It has a characteristic role in systemic inflammation in numerous disease conditions, including rheumatoid arthritis, and psoriatic arthritis.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/interleukin-6-inhibitors-therapeutics-pipeline/report-sample

The positive clinical results from IL-6 inhibitors drug candidates have been driving the pipeline growth. GlaxoSmithKline plc presented results from two pivotal Phase III studies (NCT01606761; NCT02019472) evaluating subcutaneous sirukumab. In both the studies, sirukumab met the primary endpoint showing significant improvement in the signs and symptoms of moderately to severely active rheumatoid arthritis compared to placebo.

In January 2017, Tiziana Life Sciences plc acquired an exclusive world-wide license for NI-1201, a fully human anti-IL-6R monoclonal antibody (mAb), from Novimmune SA. In exchange for the exclusive license from Novimmune SA, Tiziana Life Sciences plc agreed to an upfront cash payment, milestone payments, and a royalty on future sales.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=interleukin-6-inhibitors-therapeutics-pipeline

Some of the key players developing drugs for the treatment of IL-6 inhibitors therapeutics include GlaxoSmithKline plc, Chugai Pharmaceutical Co., Ltd., Vitaeris Inc. and others.

OX-40 Receptor Agonist Therapeutics - Pipeline Review 2017

The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development. OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients.

Explore Report sample at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline/report-sample

Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.

In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=ox40-receptor-agonist-therapeutics-pipeline

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook